Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 1
2018 2
2019 1
2020 3
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB. Brown AJH, et al. Among authors: molloy c. Cell. 2021 Nov 24;184(24):5886-5901.e22. doi: 10.1016/j.cell.2021.11.001. Cell. 2021. PMID: 34822784 Free article. Clinical Trial.
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.
Bradley SJ, Molloy C, Valuskova P, Dwomoh L, Scarpa M, Rossi M, Finlayson L, Svensson KA, Chernet E, Barth VN, Gherbi K, Sykes DA, Wilson CA, Mistry R, Sexton PM, Christopoulos A, Mogg AJ, Rosethorne EM, Sakata S, John Challiss RA, Broad LM, Tobin AB. Bradley SJ, et al. Among authors: molloy c. Nat Chem Biol. 2020 Mar;16(3):240-249. doi: 10.1038/s41589-019-0453-9. Epub 2020 Feb 20. Nat Chem Biol. 2020. PMID: 32080630 Free article.
Chemogenetics defines receptor-mediated functions of short chain free fatty acids.
Bolognini D, Barki N, Butcher AJ, Hudson BD, Sergeev E, Molloy C, Moss CE, Bradley SJ, Le Gouill C, Bouvier M, Tobin AB, Milligan G. Bolognini D, et al. Among authors: molloy c. Nat Chem Biol. 2019 May;15(5):489-498. doi: 10.1038/s41589-019-0270-1. Epub 2019 Apr 15. Nat Chem Biol. 2019. PMID: 30992568
High-Content Screening and Computational Prediction Reveal Viral Genes That Suppress the Innate Immune Response.
Ng TL, Olson EJ, Yoo TY, Weiss HS, Koide Y, Koch PD, Rollins NJ, Mach P, Meisinger T, Bricken T, Chang TZ, Molloy C, Zürcher J, Chang RL, Mitchison TJ, Glass JI, Marks DS, Way JC, Silver PA. Ng TL, et al. Among authors: molloy c. mSystems. 2022 Apr 26;7(2):e0146621. doi: 10.1128/msystems.01466-21. Epub 2022 Mar 23. mSystems. 2022. PMID: 35319251 Free PMC article.
M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease.
Dwomoh L, Rossi M, Scarpa M, Khajehali E, Molloy C, Herzyk P, Mistry SN, Bottrill AR, Sexton PM, Christopoulos A, Conn J, Lindsley CW, Bradley SJ, Tobin AB. Dwomoh L, et al. Among authors: molloy c. Sci Signal. 2022 Nov 15;15(760):eabm3720. doi: 10.1126/scisignal.abm3720. Epub 2022 Nov 15. Sci Signal. 2022. PMID: 36378750
Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease.
Scarpa M, Molloy C, Jenkins L, Strellis B, Budgett RF, Hesse S, Dwomoh L, Marsango S, Tejeda GS, Rossi M, Ahmed Z, Milligan G, Hudson BD, Tobin AB, Bradley SJ. Scarpa M, et al. Among authors: molloy c. Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):e2107389118. doi: 10.1073/pnas.2107389118. Proc Natl Acad Sci U S A. 2021. PMID: 34893539 Free PMC article.
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo.
Thompson KJ, Khajehali E, Bradley SJ, Navarrete JS, Huang XP, Slocum S, Jin J, Liu J, Xiong Y, Olsen RHJ, Diberto JF, Boyt KM, Pina MM, Pati D, Molloy C, Bundgaard C, Sexton PM, Kash TL, Krashes MJ, Christopoulos A, Roth BL, Tobin AB. Thompson KJ, et al. Among authors: molloy c. ACS Pharmacol Transl Sci. 2018 Sep 14;1(1):61-72. doi: 10.1021/acsptsci.8b00012. Epub 2018 Jul 27. ACS Pharmacol Transl Sci. 2018. PMID: 30868140 Free PMC article.
Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes.
Bradley SJ, Molloy C, Bundgaard C, Mogg AJ, Thompson KJ, Dwomoh L, Sanger HE, Crabtree MD, Brooke SM, Sexton PM, Felder CC, Christopoulos A, Broad LM, Tobin AB, Langmead CJ. Bradley SJ, et al. Among authors: molloy c. Mol Pharmacol. 2018 Jun;93(6):645-656. doi: 10.1124/mol.118.111872. Epub 2018 Apr 25. Mol Pharmacol. 2018. PMID: 29695609 Free PMC article.
13 results